These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31747859)

  • 1. Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.
    Wang H; Liao P; Zeng SX; Lu H
    Cancer Biol Ther; 2020; 21(3):269-277. PubMed ID: 31747859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.
    Liao P; Zeng SX; Zhou X; Chen T; Zhou F; Cao B; Jung JH; Del Sal G; Luo S; Lu H
    Mol Cell; 2017 Dec; 68(6):1134-1146.e6. PubMed ID: 29225033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
    Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
    Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It takes a team: a gain-of-function story of p53-R249S.
    Wang H; Liao P; Zeng SX; Lu H
    J Mol Cell Biol; 2019 Apr; 11(4):277-283. PubMed ID: 30608603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.
    He XX; Zhang YN; Yan JW; Yan JJ; Wu Q; Song YH
    Tumour Biol; 2016 Jan; 37(1):807-15. PubMed ID: 26250460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
    Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
    Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.
    Liu Y; Li Z; Zhang J; Liu W; Guan S; Zhan Y; Fang Y; Li Y; Deng H; Shen Z
    Br J Cancer; 2024 Jul; 131(2):243-257. PubMed ID: 38824222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
    Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
    PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of p53-R249S on the Suppression of Hepatocellular Carcinoma Cells Survival Induced by Podophyllum Derivatives.
    Chen H; Zhang M; Wang Z; Li L; Li Q; Wang H
    Anticancer Agents Med Chem; 2020; 20(7):865-874. PubMed ID: 32067620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
    Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
    Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
    Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma.
    Gao Y; Lin LP; Zhu CH; Chen Y; Hou YT; Ding J
    Cancer Biol Ther; 2006 Aug; 5(8):978-85. PubMed ID: 16855382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.